Senda Ajroud-Driss

Grants

Grants per year 1999 2020 2021 2022 2026

• 31 Active
• 40 Finished

Grants per year

Search results

• Active

  (OE) Prot #CNMAu8.EAP02: A Second Expanded Access Protocol for Amyotrophic Lateral Sclerosis with CNM-Au8

  Ajroud-Driss, S.

  Clene Nanomedicine, Inc.

  5/11/23 → 5/11/26

  Project: Research project

• Prot #QRL-201-01: A Multi-center, Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety and Tolerability of Qrl-201 in Amyotrophic Lateral Sclerosis

  Ajroud-Driss, S.

  Worldwide Clinical Trials, Inc., QurAlis Corporation

  4/6/23 → 4/6/24

  Project: Research project

• HEALEY ALS Platform Trial Regimen-Specific Appendix (RSA) G to Master Protocol DNL343

  Ajroud-Driss, S.

  Massachusetts General Hospital, Denali Therapeutics Inc.

  3/23/23 → 12/4/24

  Project: Research project

• Longitudinal Biofluids Core

  Ajroud-Driss, S. & Ajroud-Driss, S.

  Target ALS Foundation, Inc.

  11/1/22 → 10/31/24

  Project: Research project

• An Expanded Access Protocol of Intravenous Trehalose Injection 90 mg/mL Treatment of Patients with Amyotrophic Lateral Sclerosis

  Ajroud-Driss, S.

  Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke

  9/28/22 → 8/31/25

  Project: Research project

• Clinic-based Multicenter ALS Natural History Data Collection

  Ajroud-Driss, S. & Ajroud-Driss, S.

  University of Minnesota, Food and Drug Administration

  9/20/22 → 8/31/26

  Project: Research project

  • Data Collection 100%
  • Real World 100%
  • Data Repository 100%
  • data 100%
  • Subject 66%

• A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following Study MT-1186-A02 in Subjects with Amyotrophic Lateral Scle

  Ajroud-Driss, S.

  ICON Clinical Research, LLC, Mitsubishi Tanabe Pharma America, Inc.

  8/8/22 → 8/8/25

  Project: Research project

• Prot#A35-006: EXPANDED ACCESS TRIAL OF AMX0035 FOR AMYOTROPHIC LATERAL SCLEROSIS: An Intermediate Size, Expanded Access Protocol to Provide AMX0035, A Fixed Combination of Sodium Phenylbutyrate(PB) and Taurursodiol (TURSO), for the Treatment of Adult Pati

  Ajroud-Driss, S.

  Amylyx Pharmaceuticals, Inc.

  6/8/22 → 6/8/25

  Project: Research project

• Cure SMA Care Center Network and Clinical Data Registry

  Ajroud-Driss, S.

  Families of Spinal Muscular Atrophy

  6/1/22 → 12/31/23

  Project: Research project

• Prot#16970: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SAR443820 in Adult Participants with Amyotrophic Lateral Sclerosis, Followed by an Open-Label Extension

  Ajroud-Driss, S.

  Sanofi US Services Inc.

  3/29/22 → 3/29/25

  Project: Research project

• Prot#WP-0512-003: A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)

  Ajroud-Driss, S.

  DP Clinical, Inc., Woolsey Pharmaceuticals, Inc.

  3/3/22 → 3/22/25

  Project: Research project

• HEALEY ALS Platform Trial Regimen-Specific Appendix (RSA) E to Master Protocol TREHALOSE S-005

  Ajroud-Driss, S.

  Massachusetts General Hospital, NexMed, Inc.

  3/1/22 → 12/4/24

  Project: Research project

• Protocol Number: A35-004 - Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)

  Ajroud-Driss, S.

  Julius Clinical Research B.V, Amylyx Pharmaceuticals, Inc.

  1/12/22 → 1/12/25

  Project: Research project

• Prot #233AS303: A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

  Ajroud-Driss, S.

  DrugDev Inc., Biogen MA Inc.

  8/12/21 → 8/12/24

  Project: Research project

• Prot #BASICHR0053: Evaluation of digital technologies for home-based assessment of ALS patients

  Ajroud-Driss, S.

  Novartis Pharmaceuticals Corporation

  8/3/21 → 12/6/24

  Project: Research project

• Prot# VMALS-002-2: A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety of Engensis in Participants with Amyotrophic Lateral Sclerosis

  Ajroud-Driss, S.

  Worldwide Clinical Trials, Inc., ViroMed Co., Ltd.

  4/29/21 → 4/29/24

  Project: Research project

• Prot# MT-1186-A02: A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)

  Ajroud-Driss, S.

  ICON Clinical Research, LLC, Mitsubishi Tanabe Pharma America, Inc.

  3/16/21 → 3/16/24

  Project: Research project

• HEALEY ALS Platform Trial Regimen-Specific Appendix (RSA) B to Master Protocol Verdiperstat | Home Spirometry and Open-Label Extension (OLE) Period

  Ajroud-Driss, S.

  Massachusetts General Hospital, Biohaven Pharmaceuticals, Inc.

  3/15/21 → 3/14/24

  Project: Research project

• HEALEY ALS Platform Trial Regimen-Specific Appendix (RSA) C to Master Protocol CNM-Au8 | Home Spirometry and Open-Label Extension (OLE) Period

  Ajroud-Driss, S. & Ajroud-Driss, S.

  Massachusetts General Hospital, Clene Nanomedicine, Inc.

  3/15/21 → 3/14/24

  Project: Research project

• HEALEY ALS Platform Trial Regimen-Specific Appendix (RSA) A to Master Protocol ZILUCOPLAN | Home Spirometry and Open-Label Extension (OLE) Period

  Ajroud-Driss, S.

  Massachusetts General Hospital, Ra Pharmaceuticals, Inc.

  3/15/21 → 3/14/24

  Project: Research project

• Prot#AB19001: A Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination with Riluzole Versus Placebo in Combination with Riluzole in the Treatmen

  Ajroud-Driss, S.

  AB Science

  2/26/21 → 2/26/24

  Project: Research project

• Prot# 233AS102: An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 M

  Ajroud-Driss, S.

  Quintiles, Inc., Biogen MA Inc.

  11/24/20 → 9/30/25

  Project: Research project

• HEALEY ALS Platform Trial Regimen-Specific Appendix (RSA) D to Master Protocol Pridopidine | Double-Blind Phase

  Ajroud-Driss, S. & Ajroud-Driss, S.

  Massachusetts General Hospital

  11/20/20 → 12/31/23

  Project: Research project

• Oxidative Markers and Efficacy in ALS/MND Phenotypes Treated with Edaravone: Proof of Concept

  Ajroud-Driss, S.

  Loma Linda University, Mitsubishi Tanabe Pharma America, Inc.

  9/2/20 → 9/2/24

  Project: Research project

• HEALEY ALS Platform Trial Regimen-Specific Appendix (RSA) C to Master Protocol CNM-Au8 | Double-Blind Phase

  Ajroud-Driss, S. & Ajroud-Driss, S.

  Massachusetts General Hospital

  3/23/20 → 12/31/23

  Project: Research project